Cargando…
Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases
SIMPLE SUMMARY: Standard treatment protocol for PIPAC consists of three procedures and completion of treatment has been shown to be prognostic of improved survival. The aim of this study was to identify predictors for completion of treatment. This retrospective multicentric cohort study included all...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139612/ https://www.ncbi.nlm.nih.gov/pubmed/35626160 http://dx.doi.org/10.3390/cancers14102557 |
_version_ | 1784714900054999040 |
---|---|
author | Balmer, Aurélie Clerc, Daniel Toussaint, Laura Sgarbura, Olivia Taïbi, Abdelkader Hübner, Martin Teixeira Farinha, Hugo |
author_facet | Balmer, Aurélie Clerc, Daniel Toussaint, Laura Sgarbura, Olivia Taïbi, Abdelkader Hübner, Martin Teixeira Farinha, Hugo |
author_sort | Balmer, Aurélie |
collection | PubMed |
description | SIMPLE SUMMARY: Standard treatment protocol for PIPAC consists of three procedures and completion of treatment has been shown to be prognostic of improved survival. The aim of this study was to identify predictors for completion of treatment. This retrospective multicentric cohort study included all patients with peritoneal metastases undergoing PIPAC at three PIPAC expert centers. Overall, 183 patients had 517 PIPACs. Bimodal treatment was found as an independent predictive factor for completing the three procedures (OR = 4.202, 95%CI [1.813, 10.630], p < 0.001), as well as prior bowel obstruction (OR = 0.389, 95%CI [0.153, 0.920], p = 0.037). In conclusion, the absence of ascites and prior bowel obstruction can help to select patients suitable for PIPAC. Best results seem to be achieved when PIPAC is combined with systemic chemotherapy. ABSTRACT: Background: The standard treatment protocol for PIPAC consists of three procedures. Completion of treatment has been shown to be prognostic of improved survival. The aim of this study was to identify predictors for completion of treatment. Methods: Retrospective multicentric cohort study of patients with peritoneal metastases undergoing PIPAC in three PIPAC expert centers. Per protocol (PP) treatment was defined as patients receiving ≥3 PIPACs and was compared to patients receiving <3. Results: Overall, 183 patients had 517 PIPACs. The main reasons for stopping PIPAC were disease progression in 50% patients, bowel obstruction in 15%, patient’s refusal to pursue in 10%, conversion to cytoreductive surgery in 7%, and medical reasons in 8%. Overall, 95 patients (52%) had PP treatment. The PP median OS was 17 vs. 7 months, p = 0.001. PP patients had r ascites (410 ± 100 mL vs. 960 ± 188 mL, p = 0.001), no prior history of bowel obstruction (12% vs. 24%, p = 0.028), and more bimodal treatment (39% vs. 13%, p < 0.001). After multiple regression, bimodal treatment was found as an independent predictive factor for completing PP (OR = 4.202, 95%CI [1.813, 10.630], p < 0.001), along with prior bowel obstruction (OR = 0.389, 95%CI [0.153, 0.920], p = 0.037). Conclusion: The absence of ascites and prior bowel obstruction can help to select patients suitable for PIPAC. Best results seem to be achieved when PIPAC is combined with systemic chemotherapy. |
format | Online Article Text |
id | pubmed-9139612 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91396122022-05-28 Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases Balmer, Aurélie Clerc, Daniel Toussaint, Laura Sgarbura, Olivia Taïbi, Abdelkader Hübner, Martin Teixeira Farinha, Hugo Cancers (Basel) Article SIMPLE SUMMARY: Standard treatment protocol for PIPAC consists of three procedures and completion of treatment has been shown to be prognostic of improved survival. The aim of this study was to identify predictors for completion of treatment. This retrospective multicentric cohort study included all patients with peritoneal metastases undergoing PIPAC at three PIPAC expert centers. Overall, 183 patients had 517 PIPACs. Bimodal treatment was found as an independent predictive factor for completing the three procedures (OR = 4.202, 95%CI [1.813, 10.630], p < 0.001), as well as prior bowel obstruction (OR = 0.389, 95%CI [0.153, 0.920], p = 0.037). In conclusion, the absence of ascites and prior bowel obstruction can help to select patients suitable for PIPAC. Best results seem to be achieved when PIPAC is combined with systemic chemotherapy. ABSTRACT: Background: The standard treatment protocol for PIPAC consists of three procedures. Completion of treatment has been shown to be prognostic of improved survival. The aim of this study was to identify predictors for completion of treatment. Methods: Retrospective multicentric cohort study of patients with peritoneal metastases undergoing PIPAC in three PIPAC expert centers. Per protocol (PP) treatment was defined as patients receiving ≥3 PIPACs and was compared to patients receiving <3. Results: Overall, 183 patients had 517 PIPACs. The main reasons for stopping PIPAC were disease progression in 50% patients, bowel obstruction in 15%, patient’s refusal to pursue in 10%, conversion to cytoreductive surgery in 7%, and medical reasons in 8%. Overall, 95 patients (52%) had PP treatment. The PP median OS was 17 vs. 7 months, p = 0.001. PP patients had r ascites (410 ± 100 mL vs. 960 ± 188 mL, p = 0.001), no prior history of bowel obstruction (12% vs. 24%, p = 0.028), and more bimodal treatment (39% vs. 13%, p < 0.001). After multiple regression, bimodal treatment was found as an independent predictive factor for completing PP (OR = 4.202, 95%CI [1.813, 10.630], p < 0.001), along with prior bowel obstruction (OR = 0.389, 95%CI [0.153, 0.920], p = 0.037). Conclusion: The absence of ascites and prior bowel obstruction can help to select patients suitable for PIPAC. Best results seem to be achieved when PIPAC is combined with systemic chemotherapy. MDPI 2022-05-23 /pmc/articles/PMC9139612/ /pubmed/35626160 http://dx.doi.org/10.3390/cancers14102557 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Balmer, Aurélie Clerc, Daniel Toussaint, Laura Sgarbura, Olivia Taïbi, Abdelkader Hübner, Martin Teixeira Farinha, Hugo Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases |
title | Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases |
title_full | Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases |
title_fullStr | Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases |
title_full_unstemmed | Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases |
title_short | Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases |
title_sort | selection criteria for pressurized intraperitoneal aerosol chemotherapy (pipac) treatment in patients with peritoneal metastases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139612/ https://www.ncbi.nlm.nih.gov/pubmed/35626160 http://dx.doi.org/10.3390/cancers14102557 |
work_keys_str_mv | AT balmeraurelie selectioncriteriaforpressurizedintraperitonealaerosolchemotherapypipactreatmentinpatientswithperitonealmetastases AT clercdaniel selectioncriteriaforpressurizedintraperitonealaerosolchemotherapypipactreatmentinpatientswithperitonealmetastases AT toussaintlaura selectioncriteriaforpressurizedintraperitonealaerosolchemotherapypipactreatmentinpatientswithperitonealmetastases AT sgarburaolivia selectioncriteriaforpressurizedintraperitonealaerosolchemotherapypipactreatmentinpatientswithperitonealmetastases AT taibiabdelkader selectioncriteriaforpressurizedintraperitonealaerosolchemotherapypipactreatmentinpatientswithperitonealmetastases AT hubnermartin selectioncriteriaforpressurizedintraperitonealaerosolchemotherapypipactreatmentinpatientswithperitonealmetastases AT teixeirafarinhahugo selectioncriteriaforpressurizedintraperitonealaerosolchemotherapypipactreatmentinpatientswithperitonealmetastases |